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Conclusion: Although individuals vaccinated in 2017-2018 had high antibody titers against the egg-50 adapted vaccine strain, antibody responses to cell-grown circulating viruses may not be sufficient to 51 provide protection, likely due to egg-adaptation in the vaccine. 52
The 2017-2018 influenza season was severe in the United States, resulting in the highest rate of 53 influenza-related hospitalizations since the Centers for Disease Control and Prevention (CDC) began 54 including adults in inpatient surveillance [1] . Although the influenza A(H3N2) viruses that circulated in 55 the US belonged to multiple genetic groups, they were all considered antigenically similar to cell-grown 56 vaccine strain reference viruses [2] . However, the majority of available influenza vaccines are produced 57 in eggs and vaccine effectiveness (VE) was low in preventing adult influenza A(H3N2) infections in 2017-58 2018 [3] . While the inadequate VE against A(H3N2) viruses was highlighted by the intensity of the 2017-59 2018 outbreak, the national level estimates for A(H3N2) vaccine effectiveness were consistent with 60 observations of relatively low VE against this subtype throughout the past decade [4] . 61
A common factor over the last several years of low VE against influenza A(H3N2) is that changes to the 62 virus occur during its adaptation to eggs for vaccine production. Studies have suggested that changes 63 required to adapt influenza viruses for growth in eggs may have contributed to low VE in years with 64 influenza A(H3N2) circulation, including 2012-2013, 2016-2017, and this most recent season [5] [6] [7] . Egg-65 related changes can happen in multiple hemagglutinin epitopes and those egg-adaptation sites of 66 concern have changed since the 2014-2015 season. Specifically, influenza A(H3N2) viruses belonging to 67 the 3C.2a genetic group, which emerged in 2014-2015, acquired a glycosylation site in the 68 hemagglutinin antigenic site B [6] [7] [8] . This glycosylation site is lost during adaptation to eggs, and, as a 69 result, human and ferret serum raised against egg-adapted A(H3N2) vaccines have shown reduced 70 inhibition of recently circulating viruses [7, 9] . 71
During the severe 2017-2018 influenza season, we carried out a study of influenza vaccine effectiveness 72 among inpatients with acute respiratory illness (ARI) as part of the Centers for Disease Control and 73
Prevention (CDC) sponsored Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). 74
Preliminary vaccine effectiveness for the prevention of hospitalization due to influenza was estimated to 75 be 16% and was not statistically significant [10] . At the HAIVEN site in Michigan, serum specimens were 76 collected shortly after illness onset, representing pre-infection serologic immune status. Associations 77 between antibody titers and influenza vaccination and A(H3N2) infection status were assessed, 78 comparing antibody against egg-and cell-grown vaccine strains and a panel of wild-type viruses 79 representing those that circulated. 80
METHODS 81

Study Population 82
Adult (≥18 years) patients hospitalized for treatment of acute respiratory illnesses at the University of 83 Michigan (UM) Hospital in Ann Arbor were prospectively enrolled in a case-test negative design study of 84 influenza vaccine effectiveness during the 2017-2018 influenza season using previously described 85 methods [11] . All patients were enrolled ≤10 days from illness onset during active influenza circulation. 86
Participants provided informed consent, completed an enrollment interview, and had throat and nasal 87 swab specimens collected for influenza identification by RT-PCR using the CDC Influenza Division 88 protocol. As part of the enrollment interview, participants rated their general health prior to the onset 89 of their current illness (excellent, very good, good, fair, poor), and responded to a series of 5 questions 90 assessing difficulties with various tasks to define frailty status [11, 12] . General health was treated as a 91 dichotomous variable (≥good vs. ≤fair), and participants were considered frail if they reported 92 difficulties in ≥3 of the 5 elements of the frailty interview. Influenza vaccination status was documented 93 by electronic medical record and state vaccination registry. 94
The institutional review board at the University of Michigan Medical School and Centers for Disease 95
Control and Prevention reviewed and approved the study. 96
Serologic analysis 97
Available residual clinical serum specimens collected after hospital admission were retrieved (0-9 days 98 after illness onset). Specimens were considered to represent pre-infection serologic status, prior to a de 99 novo antibody response to the incident illness. Among participants enrolled as of January 31, 2018 with 100 available serum specimens, we selected all 15 influenza A(H3N2) positive cases identified to date and 15 101 influenza negative controls matched (nearest neighbor) on age and date of enrollment. 102
Microneutralization assays (MN) were performed using MDCK-SIAT1 cells [13, 14] Briefly, sera were heat 103 inactivated and twofold serial diluted, then mixed with 100 50% tissue culture infection dose (TCID50) of 104 A(H3N2) viruses and incubated at 37 o C 5% CO2 for 1 hr. The virus-sera mixture was used to infect 1.5 x 105 Antibody titers were calculated as the reciprocal of the highest dilution that neutralized 50% of virus 119 infectivity (MN) or inhibited NA activity (ELLA). Titers below the limits of detection for each assay (i.e., 120 <10) were denoted as half the threshold value (i.e., 5). 121
Sequencing, phylogenetics and structure analysis 122
To characterize the viruses circulating in our source population during the study period, we identified all 123 29 A(H3N2) positive specimens with RT-PCR cycle threshold < 30 from University of Michigan 124 participants enrolled during the full surveillance period (November 27, 2017, April 24, 2018). Six of these 125 29 were included as cases in the serologic analyses described above; the remaining 9 cases had RT-PCR 126 cycle threshold ≥30. Segment 4 was amplified from extracted viral RNA using the SuperScript III One-127
Step RT-PCR Platinum Taq HiFi Kit (Invitrogen 12574) and primers HA_H3N2_F (5' 128 AGCAAAAGCAGGGGATAATTCTATTAACCATG 3') and HA_H3N2_R (5' 129 AGTAGAAACAAGGGTGTTTTTAATTAATGCACTC 3'). The thermocycler protocol was: 50 C for 60 min then 130 94 C for 2 min then 30 cycles of 94 C for 30 sec, 54 C for 30 sec, 68 C for 3 min, followed by a final 5 min 131 extension at 68˚C. All RT-PCR products were purified prior to Sanger sequencing. Twenty-three samples 132 yielded sequence of sufficient quality for subsequent analysis. 133
Additional reference sequences representing circulating genetic groups were identified using publicly 134 available sources [16] and downloaded from GISAID and GenBank (for all strains and reference numbers 135 see Supplementary Table 1 ). Sequences were aligned using MUSCLE [17] with default parameters in 136 MegAlign Pro Version: 13.0.0 (Lasergene). The alignments were trimmed to the HA coding region using 137
Aliview v.1.23 [18] . Nucleotide substitution model selection was performed using jmodeltest v2.1.10 138 [19] . Maximum likelihood phylogenetic trees were generated in RAxML v8 [20] (median: 37 years), 53% were female, 63% were white race, 60% received an influenza vaccine, 38% 175 reported fair or poor general health, and 41% were frail. Cases and controls were comparable in terms 176 of age, sex, race, and date of enrollment (Table 2) . Control subjects were more likely to report fair or 177 poor general health, were more likely to be frail, and were more likely to be vaccinated; however, these 178 differences were not statistically significant. Serum specimens were collected <5 days from illness onset 179 from 73% of cases and controls. (Figure 3 ). Interestingly, NAI titers were significantly higher for vaccinated individuals than 205 they were for unvaccinated individuals (Figure 4 all target strains, uninfected controls had higher MN titers than influenza A(H3N2) infected cases ( Figure  213 3). These differences between cases and controls were statistically significant for all cell-grown viruses 214 representative of circulating viruses (all P < 0.01), but the differences were only marginally significant for 215 antibody titers against egg-and cell-grown A/HongKong/4801/2014 vaccine strain viruses (respectively: 216 P = 0.05 and P = 0.09). In contrast, NAI titers were not substantially different comparing cases and 217 controls for either NA target (Figure 4) . 218
We used multivariable logistic regression models to determine if the apparent association between 219 antibody against egg-grown A/HongKong/4801/2014 and reduced odds of influenza A(H3N2) infection 220 was independent of the reduction in infection associated with antibody against A/Washington/16/2017, 221 the virus most similar to those that predominated in this population (Supplementary Table 2 to an individual with undetectable titer for each virus, respectively ( Figure 5A and B) . The effects of both 228 MN titers were somewhat attenuated and no longer statistically significant as estimated in adjusted 229 models. After adjustment for titers against A/Washington/16/2017, the titer required for a 50% 230 reduction in odds of infection increased to 95.3 for egg-grown A/HongKong/4801/2014 ( Figure 5C ). 231
After adjustment for titers against egg-grown A/HongKong/4801/2014, the titer required for a 50% 232 reduction in odds of infection increased to 9.3 for A/Washington/16/2017 ( Figure 5D ). 233
DISCUSSION 234
As in other parts of the United States, the intense local influenza A(H3N2) season was predominately 235 3C.2a2 [21] . These and other 3C.2a descendant viruses were well inhibited by ferret-antisera raised 236 against representative 3C.2a viruses grown in cell culture, but were not as well inhibited by antisera 237 raised against egg-grown viruses [9] . There was some circulation of 3C.3a viruses, but not during the 238 main part of the outbreak. Therefore, we focused our analysis on those 3C.2a viruses that were 239 representative of those included in the vaccine and that predominantly circulated. This allowed us to 240 focus on the role of egg adaptation, which had been hypothesized in laboratory studies to be 241 responsible for the reduced VE in 2017-18 [6, 7] . We were able to provide evidence that the antibody 242 response to influenza vaccination was specific to egg-adapted influenza A(H3N2) strains and that these 243 antibodies did not strongly correlate with protection from infection during the 2017-2018 season. 244
In this hospitalized population, MN titers against the egg-adapted influenza A/HongKong/4801/2014 245 (H3N2) strain included in the 2017-2018 influenza vaccine were significantly higher in vaccinated 246 compared to unvaccinated individuals. However, both vaccinated and unvaccinated groups had similar 247 titers against cell-grown A/HongKong/4801/2014 (H3N2). This suggests that the antibody responses to 248 vaccination in this population are highly specific to the egg-adapted strain with very little cross-reactivity 249 to the circulating virus. Although not statistically significant, there was an indication that these 250 antibodies against egg-adapted influenza A/HongKong/4801/2014 (H3N2) strain provided some level of 251 protection against infection. This may be consistent with low, but non-zero, estimated effectiveness of 252 the 2017-2018 influenza vaccine. In contrast, titers against wild-type influenza A(H3N2) 3C.2a1 and 253 3C.2a2 viruses were lower overall in this population, but they were significantly correlated with 254 protection against infection during the 2017-2018 season. These results were consistent even in models 255 accounting for correlation between antibodies against specific strains. 256
Immunologic studies have proposed mechanisms for the lack of antibody cross-reactivity between egg-257 grown and circulating viruses. A study of plasmablasts in individuals receiving influenza 258 A(H1N1)pdm2009 vaccine found that individuals with a highly-specific antibody response to a reversion 259 present in the vaccine strain had no binding to the A(H1N1) circulating strain [22] . With regards to more 260 recent H3N2 strains, similar immunologic patterns of antibody misdirection have been reported for 261 residue 160 in antigenic site B of HA [7] . Influenza A(H3N2) 3C.2a viruses that have circulated since the 262 2014-2015 season possess a K160T mutation which introduces a glycosylation to antigenic site B that 263 was not present prior to 2014-2015. This mutation is reversed in the corresponding egg-propagated 264 3C.2a egg-adapted strain present in the 2016-2017 and 2017-2018 vaccines, thus allowing the immune 265 system to focus the antibody response on this epitope which is otherwise shielded in circulating 266 strains [7] . 267 Antibody against the neuraminidase of A/HongKong/4801/2014 and A/Singapore/INFIMH-16-0019/2016 268 was not associated with protection against infection. This is in contrast to past studies, which found that 269 antibody to the neuraminidase can play a role in protection, including during the 1968 pandemic [23-270 25] . A lack of association between anti-neuraminidase antibody-mediated immunity and protection 271 could explain, in part, the high incidence of infection during the 2017-2018 influenza season. We have 272 previously demonstrated that anti-neuraminidase antibody was not associated with protection during 273 the 2014-2015 season, which was also characterized by high incidence of influenza A(H3N2) infections 274 [26] . Although neuraminidase content is not standardized in influenza vaccines, we observed that anti-275 neuraminidase antibody titers were higher among vaccinated individuals suggesting that some of the 276 existing anti-neuraminidase antibody in this population resulted from vaccination. This is consistent with 277 previous studies that have directly observed a neuraminidase directed antibody response following 278 vaccination [23, 27] . Given the lack of protection demonstrated and questions about the quality of 279 vaccine induced neuraminidase antibody [28] , it is clear that more work needs to be done to understand 280 antigenic drift of the neuraminidase, and how and when anti-neuraminidase antibodies mediate 281 protection. 282
There are now at least two influenza vaccines available in the United States that are not produced in 283 eggs. However, evidence for the effectiveness of these vaccines relative to those produced in eggs is 284 limited given that few head-to-head trials have been performed. One of these trials was carried out 285 during the 2014-2015 season with predominant circulation of antigenically drifted influenza A(H3N2), 286 and found 30% higher relative efficacy in older adults for a recombinant hemagglutinin-based vaccine 287 compared to standard egg-grown inactivated influenza vaccine [29] . Vaccines grown in eggs and in cell-288 culture were found to have similar efficacy overall in a placebo controlled trial carried out in [2007] [2008] 289 but only the cell-culture derived vaccine demonstrated statistically significant efficacy against influenza 290 A(H3N2) [30] . Because these vaccines are still relatively new to the market and production remains 291 limited, influenza vaccines produced in eggs represent the vast majority of those administered. This 292 limited use currently precludes estimation of comparative effectiveness in large-scale observational 293 studies. 294
The serum specimens in this study were collected at a single time point early during acute illness [26] . 295
We have previously described evidence that antibody measured in acute specimens such as these 296 reflects pre-infection immune status rather than a de novo response to infection. While we 297 demonstrated differences in antibody titer by vaccination status, we are unable to measure the 298 magnitude of antibody response to vaccination in the absence of a paired pre-vaccination specimen. In 299 addition, this analysis included a relatively small number of specimens from a single hospital. Because of 300 the severity of the 2017-2018 epidemic was evident early in the season we prioritized rapid serologic 301 testing of the specimens that were available to date during first half of the season. These two factors 302 may limit the broad generalizability of the results; however, the influenza viruses that circulated locally 303 overall and during the analysis period were similar to those that predominated nationwide during the 304 same season. The small sample size also precluded our ability to perform additional sub-analyses to 305 assess whether results might vary within specific age groups or by history of prior vaccination. 306
In one sense, the 2017-2018 influenza vaccine appears to have worked as intended: vaccinated 307 individuals had high antibody titers against the influenza strain included in the vaccine. While this may 308 have provided some protection, it is clear that the antibody response to vaccination was not specific 309 enough to the viruses that actually circulated to provide high levels of protection. This was likely the 310 result of changes to the vaccine strain virus from egg-adaptation. Available influenza vaccines that are 311 not manufactured in eggs may provide some hope of increased effectiveness in future years. 312
Unfortunately, these vaccines are still dependent on selecting viruses that are close antigenic matches 313 to those that will circulate and are subject to the limitations of annual strain selection timelines. This 314 underscores the need for the development of the next-generation of influenza vaccines that provide 315 better, broader, and longer lasting protection [31] . 316 
